Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
0.8399
-0.0855 (-9.24%)
At close: Nov 20, 2026, 4:00 PM EST
0.8700
+0.0301 (3.58%)
After-hours: Nov 20, 2026, 7:51 PM EST
Palisade Bio Employees
Palisade Bio had 14 employees as of December 31, 2025. The number of employees increased by 6 or 75.00% compared to the previous year. That makes Palisade Bio the 39,421st largest employer in the world and 5,798th in the United States.
Employees
14
Change (1Y)
6
Growth (1Y)
75.00%
Revenue / Employee
$35,714
Profits / Employee
-$3,121,143
Market Cap
150.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 6 | 75.00% |
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| ProQR Therapeutics | 187 |
| Entrada Therapeutics | 152 |
| InflaRx | 65 |
| Korro Bio | 58 |
| Pyxis Oncology | 56 |
| Whitehawk Therapeutics | 37 |
| Eledon Pharmaceuticals | 33 |
PALI News
- 10 days ago - Palisade Bio Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 10 days ago - Palisade Bio price target lowered to $16 from $25 at Piper Sandler - TheFly
- 10 days ago - Palisade Bio price target lowered to $5 from $7 at H.C. Wainwright - TheFly
- 11 days ago - Palisade Bio reports Q3 EPS (7c), consensus (6c) - TheFly
- 11 days ago - Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs - GlobeNewsWire
- 11 days ago - Palisade Bio Quarterly report: Q3 2026 - Filings
- 11 days ago - Palisade Bio Earnings release: Q3 2026 - Filings
- 24 days ago - Palisade Bio doses first patient in ASCENTRA-UC trial - TheFly